In Alzheimer’s, There’s A Lot Of Room Under The Radar
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
At the Alzheimer’s Association International Conference in July, a number of companies reported findings alongside headliners Lilly, Merck and AstraZeneca.
You may also be interested in...
Biogen Hedges Its Bet On Alzheimer’s With Eisai Tie-Up
The big biotech and the Japanese pharma are teaming up to develop four Alzheimer’s treatments in a collaboration that will split development costs and share profits.
Biogen Hedges Its Bet On Alzheimer’s With Eisai Tie-Up
The big biotech and the Japanese pharma are teaming up to develop four Alzheimer’s treatments in a collaboration that will split development costs and share profits.
Alzheimer’s Conference Marked By Diversity Of Approaches
Clinical trial results reported at AAIC demonstrate the variety of approaches, from novel to repurposed, in play as drugmakers attempt to delay the onset, slow the progression or even prevent the world’s second-most dreaded disease. It’s an arena in which first-in-human data can achieve rock star status.